24th Sep 2018 08:11
LONDON (Alliance News) - FTSE 100 pharmaceutical giant AstraZeneca PLC reported Monday positive results from its phase three DECLARE-TIMI 58 cardiovascular outcomes trial for Farxiga, or dapagliflozin.
In the Dapagliflozin Effect on Cardiovascular Events trial, Farxiga was tested against placebo for up to five years, in around 17,000 adults with type 2 diabetes and have multiple cardiovascular risk factors or established disease.
Farxiga met its primary safety endpoint of non-inferiority for major adverse cardiovascular events, as well as a significant reduction in hospitalisation for heart failure or cardiovascular death.
Farxiga itself is an oral, once-daily inhibitor of human sodium-glucose co-transporter, used to improve glycaemic control, as well as help with weight loss and blood pressure reduction as an addition to diet and exercise for those with type 2 diabetes.
"Farxiga has achieved a statistically-significant and clinically-important reduction in hospitalisation for heart failure or CV death in a broad range of patients with type-2 diabetes and cardiovascular risk. The results from this landmark trial are especially important since heart failure is an early and frequent complication of diabetes and associated with hospitalisations that result in a considerable societal and economic burden," said Elisabeth Bjork, head of Cardiovascular, Renal and Metabolism, Global Medicines Development.
Shares in AstraZeneca were flat at 5,672.00 pence early Monday.
Related Shares:
Astrazeneca